

Index

- Acivicin, 161–177
 biochemical pharmacology of, 161–162
 clinical pharmacokinetics of, 165–166
 combination chemotherapy with, 172–176
 neurotoxicity of, 168–172
 phase I clinical trials of, 164–165
 phase II clinical trials of, 167–168
 preclinical activity of, 162–163
 preclinical pharmacokinetics of, 165–166
 preclinical toxicology of, 163–164
 salvage inhibitors and, 175–176
- Acodazole, and schedule-dependence, 130
- Acoustic Schwannomas, 185
- Acquired immune deficiency syndrome (AIDS)
 antiretroviral drugs and, 220, 221, 222, 223, 224
 DHPG and, 208, 209
 retroviruses and, 205, 218
- Actinomycin-D
 acivicin with, 172
 extragonadal germ cell tumors (EGGCT) and, 113, 114, 120
- Acyclovir, 215
 herpes virus and, 207–208, 211
 tiazofurin-5'-monophosphate (TRMP) and, 68
- Adenosine deaminase (ADA), 233–234
 deoxycoformycin (dCF) and, 234
 immune function and, 238–239
 inhibition of, 234–238
- Adenosine kinase, and tiazofurin-5'-monophosphate (TRMP), 67–68
- S-adenosylmethionine decarboxylase, and interferon, 151
- Adhesion formation, with intraperitoneal chemotherapy, 42, 44
- Adriamycin
 extragonadal germ cell tumors (EGGCT) and, 113, 114
 interferon and, 151
 intracranial tumors and, 198
 protein-associated DNA strand breaks (PASB) and, 27
- AIDS, *see* Acquired immune deficiency syndrome (AIDS)
- AIDS-related complex (ARC), 222, 223, 224
- Alkali-labile sites
 bases for assays of, 6
 chloroethylnitrosoureas and, 10
- Alkaline elution phenomenon, 5, 20, 24
- Alkylating agents, and alkali-labile sites in assays, 6
- Alkylisocyanates, and DNA repair inhibition, 12–13
- Alkylnitrosoureas, and antitumor activity, 9
- Alpha-feto protein (AFP), with
 extragonadal germ cell tumors (EGGCT), 107, 117, 122
- Alpha interferon (IFN), 141, 214
 antiproliferative effects of, 148, 149
 differentiation and, 149–150
 drug interactions with, 151, 152
 immunomodulatory activity of, 146, 147
 intracellular proteins and cell membrane and, 150, 151
 intraperitoneal chemotherapy with, 52–53
 pharmacokinetics of, 143–144
 receptors for, 144, 145, 146
 rhinovirus infections and, 215
 tumor-associated antigens and, 150
- Amino acids, acivicin and depletion of, 172–173
- 2-amino-5-bromo-6 methyl-4-(1H)-pyrimidinones, 216

- m-AMSA
 - cell killing and, 31
 - double-strand breaks and, 27
 - protein-associated DNA strand breaks (PASB) and, 26, 27, 29
- Anthracycline, and protein-associated DNA strand breaks (PASB), 26
- Antibody activity, and interferon, 146, 147
- Antimoniotungstate, 224
- Antitumor activity
 - chloroethylnitrosoureas and, 8–9
 - guanine-06-alkyltransferase deficiency and selectivity for, 10–12
 - interferon immunomodulatory activity and, 146–147, 153–154
 - tiazofurin phosphates and, 87–88
 - topoisomerase enzymes and, 33–34
- Antiviral compounds, 205–225
 - glycosylation inhibitors and, 214
 - herpes viruses and, 206–213
 - interferons and, 214–218
 - rationale for development of, 205–206
 - retroviruses and, 218–225
- 9 B-D-arabinofuranosyladenine (Ara-A)
 - deoxycoformycin (dCF) and, 246–247
 - herpes virus and, 206–207, 219
- Ara-C, *see* Cytosine arabinoside (Ara-C)
- ARC, 222, 223, 224
- L-asparaginase
 - acivicin and, 171, 172, 173
 - intraperitoneal chemotherapy with, 40
- Aspartate transcarbamylase, and PALA, 233
- Aspartic acid, and acivicin, 170
- Astrocytomas
 - chemotherapy of, 185, 186, 189–194
 - high-grade, 189–194
 - low-grade, 194
 - tumor kinetics of, 187
- Avian myeloblastosis virus, and tiazofurin-5'-triphosphate, 89
- 5-azacytosine arabinoside, with schedule-dependence, 133
- Azidothymidine (AZT), 224–224
- AZQ, *see* Diaziridinylbenzoquinone (diaziquone) (AZQ)

- Bacterial peritonitis, with intraperitoneal chemotherapy, 43
- BCNU
 - intracranial tumors and, 190–191, 195, 197, 199, 200
 - reactions, products and antitumor activity of, 8–9, 33
 - structure of, 7, 8 (figure)
- Beta interferon (IFN), 141, 214
 - differentiation and, 149–150
 - immunomodulatory activity of, 146, 147
 - intraperitoneal chemotherapy with, 52–53
 - receptors for, 145–146
- 1-3-bis-2-chloroethyl-1-nitrosourea, *see* BCNU
- Bleomycin
 - extragonadal germ cell tumors (EGGCT) and, 112, 113, 114, 115, 120
 - interferon and, 152
 - intraperitoneal chemotherapy with, 51, 52
 - schedule-dependence with, 134
- Blood-brain barrier, and chemotherapy in intracranial tumors, 187–188, 199
- Bowel obstruction, with intraperitoneal chemotherapy, 43
- Brain stem tumors, and chemotherapy, 197–198
- Brain tumors
 - diaziridinylbenzoquinone (diaziquone) (AZQ) and, 16
 - see also* Intracranial tumors and specific cancers
- Breast carcinoma
 - acivicin and, 163, 165, 167, 168
 - interferon and, 148, 151
- E-5-2-bromovinyl-2'-deoxyuridine (BVDU), and herpes viruses, 210
- E-5-(2-bromovinyl) uracil (BVU), 210
- E-5-(2-bromovinyl) uridine (BVRU), 210
- Bropirimine, and interferon, 217
- B16 melanoma cell lines, and interferon, 151
- Burkitt's lymphoma cell lines
 - acivicin and, 163
 - cisplatin and, 20–21
 - Epstein-Barr virus (EBV) and, 205

- Calcitonin, with extragonadal germ cell tumors (EGGCT), 107
- Camptothecin, and topoisomerase I, 25, 34
- Carbamoylation
 - antitumor activity and, 8–9, 33
 - DNA repair inhibition and, 12–13
- Carbamyl phosphate synthetase II (CPS II), and acivicin, 161, 162, 173–174
- Catheters
 - intraperitoneal chemotherapy and, 42–43

- CCNU
 intracranial tumors and, 195, 197, 200
 reactions, products and antitumor activity
 of, 8–9, 33
 structure of, 7, 8 (figure)
- Central nervous system (CNS), and acivicin
 toxicity, 169–171
- Central nervous system (CNS) extragonadal
 germ cell tumors (EGGCT), 115–120
 clinical characteristics of, 115–117
 radiographic changes in, 117–118
 therapy for, 118–120
 tumor markers for, 108, 117
- Cephalosporin, for bacterial peritonitis, 43
- Cerebrospinal fluid (CSF) assays, with
 extragonadal germ cell tumors
 (EGGCT), 107, 117
- Cervical cancer, and herpes simplex type II
 (HSV-2) virus, 205
- Chemotherapy
 extragonadal germ cell tumors (EGGCT)
 and, 112–115
 interferon interactions with, 151–152
 intracranial tumors and, 185–201
see also Combination chemotherapy *and*
specific drugs
- Chloroacetaldehyde, and tiazofurin, 99
- Chloroethylation reaction, and antitumor
 activity, 8–9
- Chloroethyl diazohydroxide, 8
- 2-chloroethyl
 (methanesulfonyl)methanesulfonate
 (ClEtSoSo), 13–14
- Chloroethylnitrosoureas
 DNA filter elution methods with, 7–14
 DNA interstrand crosslinking and, 32–33
 DNA lesions and cell lethality and, 10
 DNA repair inhibition and, 12–13
 guanine-06-alkyltransferase deficiency and
 selectivity of, 10–12
 reactions, products and antitumor activity
 of, 8–9
 structures of, 7, 8 (figure)
- Choriocarcinoma
 chemotherapy for, 113
 extragonadal germ cell tumors (EGGCT)
 and, 105, 108
 Klinefelter's syndrome and, 111
- Chromosomal abnormalities, with
 extragonadal germ cell tumors
 (EGGCT), 111
- CISCA therapy, with extragonadal germ
 cell tumors (EGGCT), 114
- Cisplatin
 extragonadal germ cell tumors (EGGCT)
 and, 112–115, 120
 interferon and, 152
 interstrand crosslinking and, 11, 20–24
 intraperitoneal chemotherapy with, 41,
 44, 46–48, 51, 52
 neurotoxicity of, 47–48
 thiosulfate neutralization of, 41, 46–47
- CMV, *see* Cytomegalovirus (CMV)
- Colon carcinoma cell lines
 acivicin and, 162, 165, 167, 168
 diaziridinylbenzoquinone (diaziquone)
 (AZQ) and, 18
 intraperitoneal chemotherapy with, 51
 tiazofurin-4'-carboxamide adenine
 dinucleotide (TAD) and, 71
 TAD phosphodiesterase, 79, 80
- Combination chemotherapy
 acivicin in, 172–176
 astrocytomas and, 191
 deoxycoformycin (dCF) and, 246–247
 extragonadal germ cell tumors (EGGCT)
 and, 112, 113, 115
 intraperitoneal therapy with, 50–52
see also specific combinations
- Compound S, 224–225
- Condylomata acuminata, and interferon, 215
- Corticosteroids, with astrocytomas, 191
- Cyclophosphamide
 extragonadal germ cell tumors (EGGCT)
 and, 113, 114
 interferon interactions with, 151, 152
 intracranial tumors and, 198
- Cytarabine
 combination chemotherapy with, 51, 52
 intraperitoneal chemotherapy with, 40,
 44, 48–49, 51, 52
- Cytochrome P-450 mono-oxygenase, and
 interferon, 152
- Cytomegalovirus (CMV)
 acyclovir and, 207
 DHPG and, 208, 209
 foscarnet and, 221
- Cytosine arabinoside (Ara-C)
 acivicin and, 174, 175
 interferon and, 151
 schedule-dependence with, 129
- Cytosan, with extragonadal germ cell
 tumors (EGGCT), 120
- DCF, *see* Deoxycoformycin (dCF)

- Demethylmisonidazole, with intraperitoneal chemotherapy, 52
- Deoxyadenosine
 deoxycoformycin (dCF) and, 235–237
 tiazofurin-5'-monophosphate (TRMP) and, 67
- 2'-deoxyazacytidine, 6
- Deoxycoformycin (dCF), 233–248
 adenine nucleotides and, 243–244
 adenosine deaminase and, 233–238
 combination chemotherapy with, 246–247
 immune function and, 239
 pharmacology of, 239–244
 phase I clinical trials of, 244–245
 phase II clinical trials of, 245–246
 preclinical pharmacokinetics of, 240–241
- 1-2 deoxy-2-fluoro-1-B-D-arabinofuranosyl-5-iodocytosine (FIAC), 211
- 1-2 deoxy-2-fluoro-1-B-D-arabinofuranosyl-5-iodouracil (FIAU), 211
- 1-2 deoxy-2-fluoro-1-B-D-arabinofuranosyl-5-methyluracil (FMAU), 211–212
- 2-deoxy-D-glucose, 214
- Deoxyspergualin, and schedule-dependence, 130, 133, 134
- Dexamethasone, and medulloblastomas, 195
- Dianhydrogalactitol, and astrocytomas, 191
- Diazepam, and acivicin toxicity, 169
- Diaziridinylbenzoquinone (diaziquone) (AZQ)
 DNA filter elution methods with, 14–19, 33
 DNA lesion production and, 18–19
 mouse leukemia L1210 cell lines and, 16–18
- 1-dibromodulcitol, and malignant gliomas, 191
- 8,9-1,3-dihydroxy-2 propoxymethyl guanine (DHPG), and herpes viruses, 208–209
- Dimethylsulfoxide, and interferon, 149
- DNA filter elution methods, 3–34
 alkali-labile sites in, 6
 basic procedures common to, 3–4
 diaziridinylbenzoquinone in, 14–19, 33
 DNA chloroethylating agents in, 7–14, 32–33
 DNA-protein crosslinks in, 7
 double-strand breaks in, 5
 experimental and theoretical bases of, 3–7
 interstrand crosslinks in, 6–7
 platinum complexes in, 20–24
 protein-associated DNA strand breaks (PASB) and, 25
 single-strand breaks in, 5
 topoisomeres in, 24–32, 33–34
 use of term, 4
- DNA interstrand crosslinks
 bases for assays of, 6–7
 chloroethylnitrosoureas and, 10, 11, 32–33
 diaziridinylbenzoquinone (diaziquone) (AZQ) and, 16–18, 33
 platinum complexes and, 20–21
- DNA-protein crosslinks
 bases for assays of, 7
 chloroethylnitrosoureas and, 10
 guanine-06-alkyltransferase deficiency and, 33
- Double-strand breaks
 bases for assays of, 5
 protein-associated DNA strand breaks (PASB) and, 27–29
- Down regulation of interferon receptors, 145
- Doxorubicin
 combination chemotherapy with, 51
 interferon interactions with, 151, 152
 intraperitoneal chemotherapy with, 41, 43, 44–45, 51
- Drug therapy, *see* Chemotherapy and *specific drugs*
- EGGCT, *see* Extragenadal germ cell tumors (EGGCT)
- Elution methods, *see* DNA filter elution methods
- Embryonal carcinoma
 extragenadal germ cell tumors (EGGCT) and, 108, 121
 radiation therapy for, 112
- Endodermal sinus tumors
 extragenadal germ cell tumors (EGGCT) and, 108, 121
 therapy for, 113, 120
- Ependymomas, and chemotherapy, 197
- Epidermoid lung cancer, and acivicin, 165
- Epipodophyllotoxins, and protein-associated DNA strand breaks (PASB), 25, 31
- Epithelial ovarian cancer, and acivicin, 167
- Epstein-Barr virus (EBV)
 acyclovir and, 207
 Burkitt's lymphoma and, 205

- Erythrocytes accumulation, and tiazofurin phosphates, 85–87
- Erythro-9-(2-hydroxy-3-nonyl) adenine (EHNA), 234, 237, 238, 239, 240, 241
- Etoposide (VP-16)
 combination chemotherapy with, 51
 extragonadal germ cell tumors (EGGCT) and, 114
 intraperitoneal chemotherapy with, 50, 51
 protein-associated DNA strand breaks (PASB) and, 31–32
- Extragonadal germ cell tumors (EGGCT), 103–123
 bulk of, 110
 central nervous system (CNS) sites of, 115–120
 infants and, 121
 Klinefelter's syndrome and, 111
 origin of, 103–107
 mediastinal and retroperitoneal presentations of, 108–115
 scrotal thermography in, 107
 sites of, 107, 108
 syndromes associated with, 110–111
 testicular malignancy metastatic patterns different from, 108–110
 therapy for, 111–115
 tumor markers for, 107–108, 117, 122
 unrecognized or undifferentiated, 121–122
- Fanconi's anemia, 21
- FEAU, 212
- FIAC, 211
- FIAU, 211
- Filter elution methods, *see* DNA filter elution methods
- Fludarabine, 247
- Fluorodeoxyuridine (FdUrd)
 schedule-dependence with, 129, 131
- 5-fluorodeoxy-uridine, 5'-monophosphate (FdUMP), and acivicin, 174
- 2'-fluoro-5-ethyl-1-B-D-arabinofuanosyluracil (FEAU), 212
- 5-fluorouracil (5-FU)
 acivicin and, 174, 175
 combination chemotherapy with, 51
 interferon interactions with, 151, 152
 intracranial tumors and, 198
 intraperitoneal chemotherapy with, 40, 44, 45, 51
- FMAU, 211–212
- Folinic acid, with methotrexate, 41, 45, 46
- Foscarnet, and retroviruses, 220–221
- Friend leukemia cell lines
 interferon and, 145
- γ -aminobutyric acid, and acivicin, 170
- Gamma-glutamyltranspeptidase, and acivicin, 162
- Gamma interferon (IFN), 141, 214
 differentiation and, 149–150
 immunomodulatory activity of, 147
 receptors for, 144, 145–146
 tumor necrosis factor and, 153
- Gangliogliomas, 116
- Ganglioneuromas, 116
- Gastric carcinoma, and acivicin, 165
- Germ cell malignancies
 central nervous system (CNS) sites of, 115
 interrelationship of types of, 103
see also Extragonadal germ cell tumors (EGGCT)
- Germinomas, and extragonadal germ cell tumors (EGGCT), 104, 115, 120
- Glioblastoma, chemotherapy of, 185
- Glioblastoma multiforme, 185
 chemotherapy of, 189
see also Intracranial tumors
- Gliomas, 116
 chemotherapy in, 189, 191
 pretreatment prognostic factors in, 191
- Glutamine, and acivicin, 170
- Glutathione (GSH)
 acivicin and, 162
 interstrand crosslinking and, 24
- Glycine, and acivicin, 170
- Glycosylation inhibitors, 214
- Guanine, and tiazofurin, 63, 65
- Guanine-06-alkyltransferase deficiency, and chloroethylnitrosoureas, 10–12, 33
- Guanosine, and tiazofurin, 63
- Guanosine-5'-monophosphate (GMP),
 tiazofurin inhibition of, 63, 90
- Guanylate
 tiazofurin activity and, 63–64, 87
 tiazofurin-4'-carboxamide adenine dinucleotide (TAD) and, 70
- Hairy cell leukemia (HCL), and deoxycoformycin (dCF), 245
- Hematoporphyrin derivative, with intraperitoneal chemotherapy, 53

- Herpes simplex type I (HSV-1) virus
 acyclovir and, 207–208
 BVDU and, 210
 5-iodo-2'-deoxyuridine (IDU) and, 209
 pyrimidine analogs and, 212
- Herpes simplex type II (HSV-2) virus
 acyclovir and, 207–208
 BVDU and, 210
 cervical cancer and, 205
 5-iodo-2'-deoxyuridine (IDU) and, 209
 pyrimidine analogs and, 211, 212
- Herpes viruses
 acyclovir and, 207–208
 antiviral drugs and, 206–213
 BVDU and, 210
 DHPG and, 208–209
 5-iodo-2'-deoxyuridine (IDU) and, 209–210
 pyrimidine analogs and, 211–212
 replication of, 206
 triazole nucleosides and, 212–213
- Hexamethylene bisacetamide (HMBA), and
 schedule-dependence, 130, 133, 134, 137
- Hexamethylmelamine, in intraperitoneal
 chemotherapy, 40, 53
- HIV, and antiretroviral drugs, 218, 219, 220, 221, 222
- HL-60 human leukemic cell lines, and
 interferon, 149
- HPA-23, 224
- HT-29 human carcinoma cell lines, and
 diaziridinylbenzoquinone (diaziquone)
 (AZQ), 18
- Human chorionic gonadotropin (hCG), in
 extragonadal germ cell tumors
 (EGGCT), 107, 111, 117, 122
- 9-(2-hydroxyethoxymethyl) guanine, *see*
 Acyclovir
- Hyperthermic delivery, in intraperitoneal
 chemotherapy, 52
- Ibotenic acid, and acivicin, 170
- 5-iminodaunorubicin (5-ID), and protein-
 associated DNA strand breaks (PASB),
 26, 31
- Immunostimulant agents, with
 intraperitoneal chemotherapy, 52
- IMPD, *see* Inosinic acid dehydrogenase
 (IMPD)
- IMR-90 cell lines, and
 chloroethylnitrosoureas, 13, 18
- INF, *see* Interferon (INF)
- Inosine, and tiazofurin-5'-monophosphate
 (TRMP), 67
- Inosinic acid dehydrogenase (IMPD)
 tiazofurin and, 64–65, 86
 tiazofurin-4'-carboxamide adenine
 dinucleotide (TAD) and, 64, 70, 81–83
 tiazofurin-4'-carboxamide adenine
 dinucleotide (TAD) analogs and
 cytotoxicity studies of, 81–83
 tiazofurin-4'-carboxamide adenine
 dinucleotide-2'-phosphate (TADP)
 inhibition of, 98
 tiazofurin-5'-monophosphate (TRMP)
 and, 68
 tiazofurin phosphates and, 88
- Interferon (INF), 141–154
 anticellular activity of, 147–149
 antiviral activity of, 214–218
 classes of, 141
 differentiation and, 149–150
 drug interactions and, 151–152
 immunomodulatory activity of, 146–147
 inducers of, 215–216
 intracellular proteins and cell membrane
 and, 150–152
 intraperitoneal chemotherapy with, 52–53
 pharmacokinetics of, 143–144
 receptors for, 144–146
 research developments in, 142–143
- Intracranial tumors, 185–201
 blood-brain barrier and, 187–188
 experimental approaches to
 chemotherapy of, 198–200
 factors modulating effectiveness of
 chemotherapy in, 185–186
 general concepts of chemotherapy studies
 in, 188–189
 heterogeneity of tumor cells in, 186
 microenvironment of, 186
 tumor cell resistance in, 188
 tumor kinetics of, 187
- Intraperitoneal chemotherapy, 39–54
 adhesion formation in, 42, 44
 catheter insertion in, 42–43
 clinical trials of, 44–50
 combination chemotherapy in, 50–52
 dose-limiting toxicity in, 41–42
 drug absorption rate in, 40
 drug clearance and distribution in, 39–40,
 42
 immunostimulant and immunomodulating
 agents in, 52–53
 innovative approaches to, 52–53
 large treatment volumes in, 42

- neutralizing drugs with, 40–41
- penetration into tumor nodules and, 41
- peritonitis in, 43
- pharmacologic principles of, 39–41
- pharmacokinetic rationale for, 39
- problems associated with, 41
- radiosensitizers with, 52
- Interstrand crosslinks
 - bases for assays of, 6–7
 - chloroethylnitrosoureas and, 10, 11, 32–33
 - diaziridinylbenzoquinone (diaziquone) (AZQ) and, 16–18
 - platinum complexes and, 20–21
- 5-iodo-2'-deoxyuridine, and herpes viruses, 209–210

- Kaposi's sarcoma, and suramin, 223
- Klinefelter's syndrome, with extragonadal germ cell tumors (EGGCT), 111

- Lactate dehydrogenase (LDH), in extragonadal germ cell tumors (EGGCT), 107
- Laser light, with intraperitoneal chemotherapy, 53
- Leukemic cells
 - chloroethylnitrosoureas and, 9
 - interferon and, 145, 149
 - see also L1210 leukemia cell lines; P388 leukemia cell lines
- Lewis lung carcinoma
 - acivicin and, 174
 - tiazofurin and, 63, 67
- L1210 leukemia cell lines
 - acivicin and, 161, 162, 163, 173, 174
 - cisplatin and crosslinking in, 23
 - diaziridinylbenzoquinone (diaziquone) (AZQ) and, 16–18
 - interferon and, 151
 - m-AMSA and, 26
 - tiazofurin and, 63, 65
 - tiazofurin-4'-carboxamide adenine dinucleotide (TAD) and, 71, 72
 - tiazofurin-5'-triphosphate (TRTP) and, 90
- Lung carcinoma
 - acivicin and, 165
 - intraperitoneal chemotherapy with, 51
- Lymphoblastic leukemia, acute (ALL), and deoxycoformycin (dCF), 244
- Lymphoma
 - acivicin and, 168
 - deoxycoformycin (dCF) and, 244
 - diaziridinylbenzoquinone (diaziquone) (AZQ) and, 16
- Macrophages, and interferon, 147
- Malignant ascites, with intraperitoneal 5-fluorouracil, 45
- m-AMSA
 - cell killing and, 31
 - double-strand breaks and, 27
 - protein-associated DNA strand breaks (PASB) and, 26, 27, 29
- MeCCNU
 - guanine-06-alkyltransferase deficiency and selectivity of, 10
 - reactions, products and antitumor activity of, 8–9
 - structure of, 7, 8 (figure)
- Mediastinal extragonadal germ cell tumors (EGGCT), 108–115
- Medulloblastomas, chemotherapy for, 195–197
- Melanoma cell lines
 - acivicin and, 165, 168
 - interferon and, 151
- Melphalan, in intraperitoneal chemotherapy, 44, 49
- Meningiomas, and chemotherapy, 198
- Merbarone, and schedule-dependence, 133
- 6-mercaptopurine, and intracranial tumors, 197
- Mesothelioma
 - acivicin and, 168
 - intraperitoneal cisplatin and, 48
- Methotrexate (MTX)
 - folinic acid neutralization of, 41, 45, 46
 - interferon and, 152
 - intracranial tumors and, 198, 199
 - intraperitoneal chemotherapy with, 41, 44, 45–46, 52
 - medulloblastomas and, 195
 - schedule-dependence with, 129, 131
 - β -methylene tiazofurin-4'-carboxamide adenine dinucleotide (TAD), 81
- Methyl-CCNU, and intracranial tumors, 190–191, 200
- 2-methyl-9-hydroxyellipticinum (2-Me-9-OH-E+), and protein-associated DNA strand breaks (PASB), 26, 29, 31
- MiaPaCa-2 human pancreatic carcinoma cell line, and acivicin, 163
- Misonidazole, with intraperitoneal chemotherapy, 52

- Mithramycin, in astrocytoma, 190
- Mitomycin, in intraperitoneal chemotherapy, 49
- Mitoxantrone, in intraperitoneal chemotherapy, 45
- Mixed tumors, with extragonadal germ cell tumors (EGGCT), 108
- MOPP therapy, and intracranial tumors, 195, 197
- MTX, *see* Methotrexate (MTX)
- Murine cell lines, *see* Leukemia L1210 cell lines
- Muscimol, and acivicin, 170
- Mycosis fungoides, and deoxycoformycin (dCF), 242, 247
- Myelocytic leukemia, with intraperitoneal cytarabine, 48
- Myoblasts, and interferon, 149
- NAD, *see* Nicotinamide adenine dinucleotide (NAD)
- Nalidixic acid, and protein-associated DNA strand breaks (PASB), 29
- Natural killer (NK) cells
interferon activity and, 146–147, 217
intraperitoneal chemotherapy and, 53
- Neurotransmission, and acivicin, 170
- Neutral elution, 4
- Nicotinamide adenine dinucleotide (NAD)
minor dinucleotide metabolites of
 tiazofurin and, 93
 tiazofurin-4'-carboxamide adenine
 dinucleotide (TAD) and, 70, 73–76
 TAD phosphodiesterase, 79, 80
- Nicotinamide adenine dinucleotide (NAD)
pyrophosphorylase
minor dinucleotide metabolites of
 tiazofurin and, 92
 tiazofurin-4'-carboxamide adenine
 dinucleotide (TAD) synthesis and, 73–
 76, 77, 78, 79, 86
 tiazofurin-4'-carboxamide adenine
 dinucleotide-2'-phosphate (TADP)
 and, 96–98
 tiazofurin-5'-triphosphate (TRTP) and, 90
- Nicotinamide mononucleotide (NMN), and
 tiazofurin, 68
- Nicotinamide thiazole-4-carboxamide
 dinucleotide (NTD), 78
- Nitrogen mustard
 interstrand crosslinking and, 11
 medulloblastomas and, 195
- Nitrosoureas, with intracranial tumors, 190,
 195, 197, 198
- Non-Hodgkin's lymphoma, and suramin,
 223
- Norfloxacin, and protein-associated DNA
 strand breaks (PASB), 29
- Novobiocin, and protein-associated DNA
 strand breaks (PASB), 29
- Nucleic acid polymerases, and tiazofurin
 phosphates, 88–90
- Nucleoside-5'-monophosphate (NMN), and
 tiazofurin-4'-carboxamide adenine
 dinucleotide (TAD) synthesis, 73, 75,
 78
- OK-432, with intraperitoneal
 chemotherapy, 52
- 2',5'-oligoadenylate synthetase, and
 interferon, 150–151
- Oncogenes, and interferon, 151
- Ornithine decarboxylase, and interferon,
 151
- Orotidylate synthetase, 233
- Osteosarcoma cell lines, and interferon,
 144, 148
- Ovarian cancer
 acivicin and, 165, 167, 168
 intraperitoneal chemotherapy for, 44, 45,
 46, 48, 49, 51, 52, 53
- PALA
 acivicin and, 173–174, 175
 aspartate transcarbamylase and, 233
- Pancreatic carcinoma cell line, and acivicin,
 163
- Peritonitis, and intraperitoneal
 chemotherapy, 43
- L-phenylalanine mustard, and DNA
 crosslinking, 21
- Phosphonoformate, and retroviruses, 220–
 221
- Pineal body tumors, 115, 116, 117, 120
- Pituitary tumors, 185
- Platinum complexes
 DNA crosslinking and, 20–21
 DNA filter elution methods with, 20–24
 DNA repair and, 21–24
- Poly (I)-Poly (C), and interferon, 215–216
- Prednisone, and ependymomas, 197
- Primordial germ cells (PGG), 103–104

- Procarbazine, and intracranial tumors, 191, 195, 197, 198
- Promyelocytic leukemic cell lines, and interferon, 149
- Protein-associated DNA strand breaks (PASB)
 cell killing and, 31–32
 concept of, 24–25
 DNA filter elution methods and, 29
 double-strand breaks and, 27–29
 kinetics of, 25–27
 topoisomerases and, 30
- P388 leukemia cell lines
 acivicin and, 163, 173, 174, 175
 tiazofurin and, 63, 65
 tiazofurin-4'-carboxamide adenine dinucleotide (TAD) and, 71, 72, 73
 tiazofurin phosphates and, 85, 88, 89
- Pulmonary carcinoma, *see* Lung carcinoma
- PVB therapy, with extragonadal germ cell tumors (EGGCT), 112, 113, 115
- Pyrazofurin, 233
- Pyrimidine, and acivicin, 173–175
- Pyrimidinones, and interferons, 216–218
- Radiation therapy
 extragonadal germ cell tumors (EGGCT) and, 112, 119
 intracranial tumors and, 185, 194, 195, 197, 198, 200
- Radiosensitizers, with intraperitoneal chemotherapy, 52
- Receptors for interferon, 144–146
- Renal cell adenocarcinoma
 acivicin and, 162
 interferon and, 148
- Reticulum cell sarcoma cell line, and acivicin, 163
- Retinoic acid, and interferon, 149
- Retroperitoneal extragonadal germ cell tumors (EGGCT), 108–115
- Retroviruses
 acquired immune deficiency syndrome (AIDS) and, 205
 antiviral drugs and, 218–225
 replication of, 206
- Rhabdomyosarcoma, 10
- Rhinovirus infections, and alpha interferon, 215
- Ribavirin, and retroviruses, 212, 218–220
- 2-B-D-ribofuranosylthiazole-4-carboxamide, *see* Tiazofurin
- Ribonucleotide reductase, and tiazofurin-5'-diphosphate, 88
- Sacrococcygeal germ cell tumors, 121
- Sarcoma cell lines, and acivicin, 162, 163
- Schedule-dependence, 129–138
 alternate testing schemes in, 135–136
 clinical testing and, 134–136
 coordination between preclinical and clinical testing in, 136–138
 moderation of acute toxicity in, 130
 preclinical pharmacokinetics in, 134
 preclinical screening for antitumor efficacy in, 132–133
 preclinical toxicology in, 132–133
 schedule-independent toxicity in, 132
 threshold effects, time dependence in, 131–132
 types of, 129–132
- Seminomas, 103
 extragonadal germ cell tumors (EGGCT) and, 104, 105, 108
 Klinefelter's syndrome and, 111
 metastatic patterns of, 109
- Single-strand breaks
 bases for assays of, 5
 chloroethylnitrosoureas and, 10
- Small bowel obstruction, with intraperitoneal chemotherapy, 43
- Small cell lung carcinoma
 acivicin and, 165
 intraperitoneal chemotherapy with, 51
- Sodium fluoride, and TAD phosphodiesterase, 84
- Sodium thiosulfate, with cisplatin, 41, 46–47, 48
- Staphylococcal peritonitis, with intraperitoneal chemotherapy, 43
- Streptozotocin
 intraperitoneal chemotherapy with, 50
 tiazofurin and, 75
- Suramin, and retroviruses, 221–223
- TAD, *see* Tiazofurin-4'-carboxamide adenine dinucleotide (TAD)
- TAD phosphodiesterase, *see* Tiazofurin-4'-carboxamide adenine dinucleotide (TAD) phosphodiesterase
- Teniposide (VM-26), and protein-associated DNA strand breaks (PASB), 31
- Teratomas

- extragonadal germ cell tumors (EGGCT)
 - and, 104, 108, 115, 121
 - Klinefelter's syndrome and, 111
- Testicular carcinoma
 - extragonadal germ cell tumors (EGGCT)
 - metastatic patterns different from, 108–110
 - EGGCT origins and, 103–107
 - incidence of, 103
 - intraperitoneal chemotherapy with, 51
 - Klinefelter's syndrome and, 111
 - tumor markers in, 107
- Thalamic gliomas, and chemotherapy, 197–198
- Thalidomide, and schedule-dependence, 134, 136–137
- Thermography, in extragonadal germ cell tumors (EGGCT), 107
- 6-thioguanine (6-TG), and acivicin, 173
- Thiotepa, with intraperitoneal chemotherapy, 52
- Thiosulfate, with cisplatin, 41, 46–47, 48
- Thymidine kinase, and acyclovir, 208
- Tiazofurin, 64–67
 - direct effect of, 65
 - future prospects for, 98–99
 - herpes viruses and, 213
 - IMP dehydrogenase inhibition by, 69
 - mechanism of action of, 63–64
 - minor dinucleotide metabolites of, 92–96
 - monophosphorylation of, 69
 - neoplastic cell lines accumulation of, 65, 66 (table)
 - nucleosides inhibiting phosphorylation of, 67–68
 - nucleic acid polymerases and, 88–90
 - secondary metabolites of, 85–98
 - tiazofurin-4'-carboxamide adenine dinucleotide (TAD) accumulation and tumor resistance to, 71–72
 - thiazole ring of, 67
- Tiazofurin-4'-carboxamide adenine dinucleotide (TAD), 70–72
 - analogs of, 80–81
 - enzymatic synthesis of, 73–76, 77
 - erythrocyte accumulation and, 86–87
 - future prospects for, 99
 - guanosine-5'-monophosphate (GMP) inhibition by, 64
 - inosinic acid dehydrogenase (IMPD) and, 64, 70, 81–83
 - nicotinamide adenine dinucleotide (NAD) pyrophosphorylase and, 73–76, 77, 78, 79
 - synthesis in vitro of, 76–77
 - TAD phosphodiesterase and breakdown of, 78–79
 - tumors resistant to tiazofurin and accumulation of, 71–72
- Tiazofurin-4'-carboxamide adenine dinucleotide-2'-phosphate (TADP), 96–98
- Tiazofurin-4'-carboxamide adenine dinucleotide (TAD) phosphodiesterase inhibition of, 83–85
 - purification and properties of, 79–80
 - TAD breakdown and, 78–79
- Tiazofurin-4'-carboxamide thiazole-4-carboxamide dinucleotide (TTD), 78, 94–96
- Tiazofurin-5'-diphosphate (TRDP), 85–92
 - IMPD inhibition and, 88
 - kinases and phosphotransferases and, 90–92
 - ribonucleotide reductase and, 88
 - therapeutic implications of, 87–88
- Tiazofurin-5'-monophosphate (TRMP), 67–85, 94
 - adenosine kinase and, 67–68
 - inosinic acid dehydrogenase (IMPD) inhibition by, 69
 - minor dinucleotide metabolites of tiazofurin and, 92
 - nicotinamide adenine dinucleotide NAD synthesis and, 73–75
 - pharmacologic properties of, 69
 - therapeutic implications of, 87–88
- Tiazofurin-5'-triphosphate (TRTP), 85–92
 - erythrocyte accumulation and, 86
 - inosinic acid dehydrogenase (IMPD) inhibition and, 88
 - kinases and phosphotransferases and, 90–92
 - minor dinucleotide metabolites of tiazofurin and, 92
 - nicotinamide adenine dinucleotide (NAD) pyrophosphorylase and, 90
 - nucleic acid polymerases and, 89
 - therapeutic implications of, 87–88
- Topoisomerases
 - anticancer action of, 33–34
 - DNA filter elution methods with, 29
 - protein-associated DNA strand breaks (PASB) and, 24–25, 30
 - self-inhibitory effects of, 29
- Topoisomerase I, and camptothecin, 25, 34
- Topoisomerase II, and protein-associated DNA strand breaks (PASB), 29, 31

- TRDP, *see* Tiazofurin-5'-diphosphate (TRDP)
- Triazole nucleosides, and herpes viruses, 212–213
- Trimetrexate, and schedule-dependence, 130, 134
- TRMP, *see* Tiazofurin-5'-monophosphate (TRMP)
- TRTP, *see* Tiazofurin-5'-triphosphate (TRTP)
- Tubercidin, 86
- Tumor-associated antigens, and interferon, 150
- Tumor markers, in extragonadal germ cell tumors (EGGCT), 107–108, 117, 122
- Tumor necrosis factor, and gamma interferon, 153
- Ultrasonography, with extragonadal germ cell tumors (EGGCT), 115
- Undescended testes, with extragonadal germ cell tumors (EGGCT), 111, 115
- Undifferentiated extragonadal germ cell tumors (EGGCT), 121–122
- Uridine kinase, and tiazofurin-5'-triphosphate (TRTP), 90–92
- U-2 OS osteosarcoma cell lines, and interferon, 144
- VAB-6 therapy, with extragonadal germ cell tumors (EGGCT), 113, 114
- VAC therapy, with extragonadal germ cell tumors (EGGCT), 120
- Vancomycin, for bacterial peritonitis, 43
- Varicella zoster virus (VZV)
acyclovir and, 207, 208
Ara-A and, 207
5-iodo-2'-deoxyuridine (IDU) and, 209
- VA-13 carcinoma cell lines, and diaziridinybenzoquinone (diaziquone) (AZQ), 18
- VB therapy, with extragonadal germ cell tumors (EGGCT), 114
- Vibarabine, and herpes virus, 206–207
- Vinblastine
extragonadal germ cell tumors (EGGCT) and, 112, 113, 114, 115, 120
interferon and, 151, 152
intracranial tumors and, 198
intraperitoneal chemotherapy with, 50
- Vincristine
extragonadal germ cell tumors (EGGCT) and, 120
medulloblastomas and, 195
- VP-16, *see* Etoposide (VP-16)